88 related articles for article (PubMed ID: 21162792)
1. [Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia].
Zhang P; Wu ZJ; Yang Y; Zhang XD
Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2826-9. PubMed ID: 21162792
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
[TBL] [Abstract][Full Text] [Related]
5. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
6. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Kirby RS; O'Leary MP; Carson C
BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety in the use of doxazosin (cardura) in the treatment of patients with benign prostatic hypertrophy (bph)].
Lopatkin NA; Aliaev IuG; Kogan MI; Loran OB; Mazo EB; Stepanov VN
Urologiia; 2003; (5):3-4. PubMed ID: 14658262
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
10. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
[TBL] [Abstract][Full Text] [Related]
11. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
Zhang Y; Wang Y; Zhang P; Zhang XD; Yang Y
Transplant Proc; 2009 Nov; 41(9):3747-51. PubMed ID: 19917379
[TBL] [Abstract][Full Text] [Related]
12. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
13. [Tonocardin (doxazosin) in treating lower urinary tract symptoms].
Mazo EB; Chepurov DA
Urologiia; 2003; (3):15-6. PubMed ID: 12846089
[TBL] [Abstract][Full Text] [Related]
14. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
15. Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia.
Keten T; Aslan Y; Balci M; Tuncel A; Bilgin O; Dilmen C; Ozdemir U; Yahsi S; Guzel O; Atan A
Urology; 2015 Jan; 85(1):189-94. PubMed ID: 25530384
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
Türkeri LN; Ozyürek M; Ersev D; Akdaş A
Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
18. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
20. [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy].
Siracusano S; Paoni A; Tomasi PA; Deriu M; Trombetta C; Belgrano E
Prog Urol; 1994 Dec; 4(6):1017-21. PubMed ID: 7533030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
